Genome and base editing for genetic hearing loss

Area of Science:

• Genetics
• Molecular Biology
• Otolaryngology

Background:

• Genome editing technologies, including CRISPR-Cas systems, offer unprecedented potential for treating genetic disorders.
• Over 100 genes associated with hereditary hearing loss have been identified, presenting numerous therapeutic targets.
• Existing research has explored various viral and non-viral vectors for gene delivery to the inner ear.

Purpose of the Study:

• To review the recent advances in genome and base editing for treating hearing loss.
• To summarize the challenges and future directions for therapeutic applications of gene editing in the inner ear.

Main Methods:

• Review of current literature on genome editing technologies and their application in hearing loss research.
• Analysis of studies demonstrating proof-of-concept for therapeutic genome and base editing in mammalian inner ear models.
• Evaluation of viral and non-viral vector systems for gene delivery to cochlear and vestibular cells.

Main Results:

• Gene editing can potentially address up to 90% of human genetic mutations.
• Successful proof-of-concept for therapeutic genome and base editing in the mammalian inner ear has been demonstrated.
• Preclinical development of gene editing therapies for hearing loss is actively ongoing.

Conclusions:

• Genome editing represents a transformative therapeutic approach for both genetic and non-genetic forms of hearing loss.
• Continued research and development are crucial to overcome challenges and realize the full potential of gene editing for hearing restoration.